Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

Journal of Clinical Oncology (JCO) Podcast · Jesus F. San Miguel

July 7, 201714m 21s

Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Original episode page

Show Notes

Normalization of PET-CT is a strong predictor for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM)

Related Article: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

← All episodes of Journal of Clinical Oncology (JCO) Podcast